Bausch Health Cos (NYSE:BHC) Director Sells $132,796.08 in Stock

Bausch Health Cos Inc. (NYSE:BHC) Director Frank Lee sold 24,456 shares of the business’s stock in a transaction that occurred on Tuesday, May 19th. The shares were sold at an average price of $5.43, for a total value of $132,796.08. Following the sale, the director owned 49,339 shares in the company, valued at approximately $267,910.77. This represents a 33.14% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Bausch Health Cos Stock Up 0.3%

Shares of BHC stock opened at $5.47 on Friday. Bausch Health Cos Inc. has a one year low of $4.41 and a one year high of $8.69. The company has a debt-to-equity ratio of 54.68, a current ratio of 1.32 and a quick ratio of 0.97. The stock has a fifty day moving average price of $5.42 and a 200 day moving average price of $6.12. The stock has a market cap of $2.04 billion, a P/E ratio of -1.69 and a beta of 0.42.

Bausch Health Cos (NYSE:BHC) last announced its quarterly earnings data on Wednesday, April 29th. The company reported $0.78 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.81 by ($0.03). The business had revenue of $2.46 billion during the quarter, compared to analyst estimates of $2.37 billion. Bausch Health Cos had a negative net margin of 11.47% and a negative return on equity of 2,922.77%. Analysts predict that Bausch Health Cos Inc. will post 4.08 earnings per share for the current year.

Analysts Set New Price Targets

A number of research analysts have commented on the stock. Royal Bank Of Canada cut their price target on shares of Bausch Health Cos from $10.00 to $9.00 and set a “sector perform” rating for the company in a research note on Monday, April 27th. Raymond James Financial reissued a “market perform” rating on shares of Bausch Health Cos in a report on Monday, January 26th. Weiss Ratings cut Bausch Health Cos from a “sell (d)” rating to a “sell (d-)” rating in a research report on Monday, May 4th. Barclays lowered their target price on shares of Bausch Health Cos from $8.00 to $7.00 and set an “equal weight” rating on the stock in a report on Wednesday, February 25th. Finally, Wall Street Zen downgraded shares of Bausch Health Cos from a “strong-buy” rating to a “buy” rating in a report on Sunday, February 15th. Four research analysts have rated the stock with a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Reduce” and an average target price of $8.00.

Hedge Funds Weigh In On Bausch Health Cos

A number of institutional investors have recently modified their holdings of the stock. Caption Management LLC grew its stake in shares of Bausch Health Cos by 101.1% during the fourth quarter. Caption Management LLC now owns 4,464 shares of the company’s stock valued at $31,000 after purchasing an additional 405,789 shares during the last quarter. Caitong International Asset Management Co. Ltd raised its position in Bausch Health Cos by 12,589.7% in the 4th quarter. Caitong International Asset Management Co. Ltd now owns 4,949 shares of the company’s stock worth $34,000 after purchasing an additional 4,910 shares during the last quarter. Northwestern Mutual Wealth Management Co. raised its position in Bausch Health Cos by 6,661.3% in the 3rd quarter. Northwestern Mutual Wealth Management Co. now owns 5,409 shares of the company’s stock worth $35,000 after purchasing an additional 5,329 shares during the last quarter. Russell Investments Group Ltd. lifted its holdings in Bausch Health Cos by 65.9% during the 2nd quarter. Russell Investments Group Ltd. now owns 7,819 shares of the company’s stock worth $51,000 after buying an additional 3,106 shares in the last quarter. Finally, Camelot Portfolios LLC bought a new position in Bausch Health Cos in the 4th quarter valued at $59,000. 78.65% of the stock is owned by institutional investors.

About Bausch Health Cos

Bausch Health Cos Inc, formerly known as Valeant Pharmaceuticals International, is a global specialty pharmaceutical company headquartered in Laval, Quebec, Canada. The company operates through two primary segments: Ophthalmology, led by its Bausch + Lomb franchise, and Diversified Brands, which encompasses prescription dermatology, gastrointestinal, neurology and branded pharmaceutical products. Bausch Health develops, manufactures and markets a range of therapeutic and over-the-counter offerings designed to address conditions such as cataracts, dry eye, glaucoma, acne, rosacea, migraine and gastrointestinal disorders.

The Ophthalmology segment under the Bausch + Lomb name provides products for eye health, including prescription drops, contact lens care solutions, intraocular lenses, surgical instruments and diagnostic devices.